UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): September 11, 2017

 

ADVAXIS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   000-28489   02-0563870
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

 

305 College Road East

Princeton, New Jersey, 08540

(Address of Principal Executive Offices)

 

(609) 452-9813

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act.
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
   
[  ] Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.[  ]

 

 

 

 
 

 

Item 2.02. Results of Operations and Financial Condition.

 

On September 11, 2017, Advaxis, Inc. (“Advaxis” or the “Company”) issued a press release announcing results of operations for the third quarter ended July 31, 2017 and providing a business update. A copy of such press release is being furnished as Exhibit 99.1.

 

Item 9.01 Financial Statements And Exhibits.

 

(d) Exhibits.
   
99.1 Press release issued by Advaxis, Inc., dated September 11, 2017.

 

  - 2 -  
     

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Advaxis, Inc.
  (Registrant)
     
Date: September 11, 2017    
     
  By: /s/ Sara M. Bonstein
    Sara M. Bonstein
    Executive Vice President and Chief Financial Officer

 

  - 3 -  
     

 

INDEX TO EXHIBITS

 

Exhibit    
Number   Description
     
99.1   Press release issued by Advaxis, Inc., dated September 11, 2017.

 

  - 4 -  
     

Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Ayala Pharmaceuticals (QX) Charts.
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Ayala Pharmaceuticals (QX) Charts.